SVM secured an invitation for CEO Kenneth To to contribute a bylined article to The Pathologist, a publication read by practicing pathologists and laboratory professionals. The piece, “Virtual Staining and the Next Era of Pathology,” ran in the June 2026 issue and focuses on the future of AI-driven pathology and virtual biomarker staining.

The byline builds on an earlier SVM-coordinated Q&A in The Pathologist and follows ViewsML’s April 2026 seed round, positioning To as a recognized voice in AI pathology as the company moves toward commercialization.